Publication — IRIC

Impact of Implementing a Bendamustine-based Conditioning Regimen on outcomes of Autologous Stem Cell Transplant in Lymphoma while Novel Cellular Therapies Emerge.

With the advent of new cellular and targeted therapies, treatment options for relapsed and refractory (r/R) lymphomas have multiplied and the optimal approach offering the best outcomes remains a matter of passionate debate. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is still considered a treatment option for chemosensitive lymphomas when cure is the expected goal. The myeloablative conditioning regimen preceding the SC infusion is regarded as the effective component of this approach. Carmustine (BCNU)-based preparative regimens such as BEAM or BEAC are considered the standard of care and have shown efficacy and low nonrelapse mortality (NRM). Comparative studies between conditioning regimens failed to identify a better option.

Publication date
October 12, 2022
Principal Investigators
Lachance S, Bourguignon A, Boisjoly JA, Bouchard P, Ahmad I, Bambace N, Bernard L, Cohen S, Delisle JS, Fleury I, Kiss T, Mollica L, Roy DC, Sauvageau G, Veilleux O, Zehr J, Chagnon M, Roy J
PubMed reference
Transplant Cell Ther 2022
PubMed ID
36243319
Affiliation
Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada; Division of Hematology, Oncology, Hematopoietic Cell Transplant and Cellular Therapy; Université de Montréal, Montréal, Québec, Canada. Electronic address: silvy.lachance@umontreal.ca.